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ABSTRACT: Background. The purpose of this study was to assess how
xerostomia affects dysphagia.
Methods. Prospective longitudinal studies of 93 patients with oropharyn-
geal cancer treated with definitive chemotherapy–intensity-modulated
radiotherapy (IMRT). Observer-rated dysphagia (ORD), patient-reported
dysphagia (PRD), and patient-reported xerostomia (PRX) assessment of
the swallowing mechanics by videofluoroscopy (videofluoroscopy score),
and salivary flow rates, were prospectively assessed from pretherapy
through 2 years.
Results. ORD grades 2 were rare and therefore not modeled. Of
patients with no/mild videofluoroscopy abnormalities, a substantial pro-
portion had PRD that peaked 3 months posttherapy and subsequently
improved. Through 2 years, highly significant correlations were observed
between PRX and PRD scores for all patients, including those with no/
mild videofluoroscopy abnormalities. Both PRX and videofluoroscopy
scores were highly significantly associated with PRD. On multivariate
analysis, PRX score was a stronger predictor of PRD than the video-
fluoroscopy score.
Conclusion. Xerostomia contributes significantly to PRD. Efforts to further
decrease xerostomia, in addition to sparing parotid glands, may translate
into improvements in PRD. VC 2015 Wiley Periodicals, Inc. Head Neck 38:
E1605–E1612, 2016
KEY WORDS: xerostomia, dysphagia, head neck cancer, patient-
reported outcomes, intensity-modulated radiotherapy (IMRT)
INTRODUCTION
Patients with oropharyngeal cancer, the majority of whom
have human papillomavirus-related (HPV-positive) oro-
pharyngeal cancer, have excellent oncologic outcomes
after chemoradiotherapy (CRT), which makes the preven-
tion of radiation-related toxicities a priority.1 Dysphagia
is a common sequel of CRT for head and neck cancer
and a major determinant of patient-reported quality of life
(QOL).2,3 Previous studies have demonstrated that CRT
can affect the mechanics of swallowing, resulting in
increased bolus transit time, decreased movement of the
tongue base toward the posterior pharyngeal wall, reduced
laryngeal elevation, and food retention in the oral cav-
ity.4,5 These changes are uncomfortable and place patients
at risk for aspiration-related complications.6 Despite
aggressive management of dysphagia with rehabilitation
and exercise regimens, many patients do not regain their
pretreatment swallowing function, and some may require
prolonged feeding tubes for nutritional support.4,7 Efforts
to characterize the functional anatomy of swallowing
using videofluoroscopy have identified organs at risk for
CRT, including pharyngeal constrictors, glottis, supraglot-
tic larynx, and upper esophagus.5,8,9 We have previously
reported our institutional experience with definitive
organ-sparing CRT for oropharyngeal cancer, demonstrat-
ing that dysphagia and its complications are reduced by
limiting the dose to the swallowing-related organs using
intensity-modulated radiotherapy (IMRT).3,8,10–12
Despite use of swallowing organ-sparing IMRT, many
patients still complain of difficulty swallowing dry foods.
There is evidence that patient-reported dysphagia (PRD)
often does not correlate with objective measures of dys-
phagia (ie, the feeling of difficulty swallowing may not
relate to the dysfunction of the swallowing struc-
tures).13–15 This disparity implies that other factors related
to eating, not involving dysfunction of the swallowing
structures, may be responsible for the sensation of dyspha-
gia. Indeed, xerostomia, another common consequence of
head and neck radiotherapy (RT), can make swallowing,
especially dry food, difficult to the point where patients
require excessive water or simply avoid such foods.16,17
Although parotid gland-sparing with IMRT in recent years
has decreased xerostomia rates, approximately 25% to
*Corresponding author: A. Eisbruch, Department of Radiation Oncology,
University of Michigan Hospital, 1500 E. Medical Center Drive, Ann Arbor MI
48109. E-mail eisbruch@umich.edu
†Current address: Department of Radiation Oncology, Winship Cancer Insti-
tute, Emory University School of Medicine, Atlanta, Georgia
Contract grant sponsor: Supported in part by National Institutes of Health (NIH)
grant PO1 CA59827 and the Newman Family Foundation.
This work was presented at the 56th Annual Meeting of American Society for
Radiation Oncology (ASTRO), San Francisco, CA, September 14–16, 2014.
HEAD & NECK—DOI 10.1002/HED APRIL 2016 E1605
50% of patients still report persistent xerostomia after
IMRT.18,19 In order to clarify the relationships between
xerostomia and dysphagia, we sought to evaluate the cor-
relations among patient-reported xerostomia (PRX), PRD,
and functional assessments of swallowing (videofluoro-
scopy) and salivary output (stimulated salivary flow [SSF]
rates) in patients who participated in prospective studies
of chemo-IMRT for oropharyngeal cancer.
MATERIALS AND METHODS
Patients and therapy
Between May 2003 and March 2011, 93 patients with
newly diagnosed stage III to IV oropharyngeal cancer
were treated on 2 prospective consecutive institutional
review board-approved studies of organ-sparing chemo-
IMRT for locally advanced oropharyngeal cancer. Patient
eligibility and treatment have been previously detailed
and were similar in both protocols.8,11,20 Seventy-three
patients were enrolled on a phase II study of chemo-
IMRT aiming to reduce dysphagia by sparing the
swallowing-related structures,8,11 and 20 patients on a
subsequent study assessed the dose-effect relationships
based on cone-beam CT-derived actually delivered organ
doses.20 IMRT prescription doses were 70 Gy to the gross
target volume primary and nodal tumor volume; 59 to 63
Gy to high-risk clinical target volumes (CTVs); and 56 to
59 Gy to low-risk CTVs, delivered over 35 daily frac-
tions. Gross target volumes and CTVs were uniformly
expanded 3 to 5 mm to create planning target volumes.
Bilateral necks were treated in all patients. IMRT treat-
ment planning was performed with intent to minimize the
dose to the parotid glands, contralateral submandibular
gland, noninvolved oral cavity, glottic and supraglottic
larynx, esophagus, and the pharyngeal constrictor
muscles, with dosimetric goals and optimization algo-
rithms, as previously detailed.8 The contralateral subman-
dibular glands were preferentially spared in the latter
years of the study period using an optimization goal of
mean dose <39 Gy, based on a previous study.21 All
patients received concurrent weekly carboplatin (area
under the curve [AUC] 5 1) and paclitaxel (30 mg/m2).
Patient-reported dysphagia and xerostomia
assessments
Three validated health-related quality of life (HRQOL)
instruments were administered to enrolled patients at pre-
treatment and 3, 6, 12, 18, and 24 months after comple-
tion of CRT; these consisted of the Head and Neck
Quality of Life (HNQOL) questionnaire,22 the University
of Washington Quality of Life (UWQOL) questionnaire,2
and the Xerostomia Questionnaire (XQ).18 PRD was
assessed using the swallowing question from the HNQOL
(HNQOL-Sw) instrument (“As a result of your head and
neck condition or treatment, over the past four weeks,
how much have you been bothered by problems with
swallowing soft foods and/or solids?”) and the UWQOL
swallowing (UWQOL-Sw) instrument (“Over the past
week, I [1] swallow normally, [2] cannot swallow certain
solid foods, [3] can only swallow soft foods, [4] can only
swallow liquid foods, [5] cannot swallow”). PRX was
assessed using a summary score of the XQ (XQ score), a
validated instrument containing 8 questions that assess
patients’ mouth and throat dryness and difficulty with
talking, chewing, swallowing, and sleeping because of
dryness.18 Four questions assess dryness during eating/
speaking, and 4 questions assess dryness while not eating.
Patients rate each question on the XQ from 0 to 10 on an
11-point ordinal Likert scale, in which higher scores indi-
cate greater dryness or discomfort because of dryness. The
HRQOL instrument individual question and summary
scores were normalized on a linear 100-point scale, with 0
representing no toxicity or negative QOL effects and 100
representing the worst possible QOL.3 Scores of 0, 25, 50,
75, and 100 approximated responses of “none,” “mild/
slight,” “moderate,” “severe,” and “extreme,” respectively.
Observer-rated dysphagia and xerostomia assessments
Observer (physician)-rated dysphagia (ORD) was graded
at each follow-up visit using the Radiation Therapy Oncol-
ogy Group/European Organization for Research and Treat-
ment of Cancer scoring system (0 5 no dysphagia;
1 5 symptomatic, able to eat regular diet; 2 5 symptomatic,
altered eating/swallowing; 3 5 symptomatic, severely
altered eating/swallowing requiring feeding tube; and
4 5 complete obstruction or perforation).23 Observer (phy-
sician)-rated xerostomia scores were not included in the
present study given our demonstration in prior studies that
observer-rating underestimated xerostomia severity com-
pared with patient-reported scores, and did not correlate
with the SSF rates, unlike the significant correlations
observed for patient-reported scores.24
Functional swallowing assessments by modified barium
swallow videofluoroscopy
Functional assessment of dysphagia was performed by
modified barium swallow videofluoroscopy, as previously
detailed.3,8 Videofluoroscopy was performed pretreatment
and at 3, 12, and 24 months posttherapy, with results
quantified using the Swallowing Performance Status Scale
score: 1 5 normal swallow; 2 5 within functional limits;
3 5 mild impairment; 4 5 mild-moderate impairment;
5 5 moderate impairment; 6 5 moderate-severe impair-
ment; and 7 5 severe impairment,25–28 as in our prior
studies.3,8,11
Salivary flow assessments
Functional assessments of xerostomia were performed
by measurements of the salivary output from the major
salivary glands, as previously described.18,21 Unstimulated
and SSF rates were measured selectively for each parotid
and submandibular gland at the same timepoints as
HRQOL assessments, as previously described.29 For anal-
ysis purposes, the sum of the SSF output (in mL/min)
from all glands was used for all analyses.
Statistical analysis
Descriptive statistics were used to calculate means and
SDs for salivary flow rates and XQ scores at pretreatment
and at 3, 6, 12, 18, and 24 months posttherapy. The prev-
alence of swallowing impairment, as measured by the
Swallowing Performance Status Scale score, of PRD, as
measured by HNQOL-Sw and UWQOL-Sw question
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scores, and of ORD was calculated at pretreatment and 3,
12, and 24 months posttherapy. The prevalence of PRD
by HNQOL-Sw and UWQOL-Sw scores was determined
for patients with no or minimal functional swallowing
impairment (Swallowing Performance Status Scale score
3) at pretreatment and 3, 12, and 24 months posttreat-
ment. Spearman rank correlation (q) was used to assess
the association between XQ score and salivary flow rates,
XQ score and HNQOL-Sw and UWQOL-Sw scores, and
Swallowing Performance Status Scale score and salivary
flow rates at each timepoint for all patients and separately
for patients with and without functional swallowing
impairment on videofluoroscopy (Swallowing Perform-
ance Status Scale scores 4 and 3, respectively).
We fitted proportional odds models to assess the associ-
ation between dysphagia and xerostomia, and conducted
univariate as well as multivariate analysis with adjustment
for covariates. The magnitude of the association was
quantified using normalized odds ratios (ORs), calculated
as the OR per SD increase in the predictors. A p val-
ue .05 was accepted as statistically significant. Statisti-
cal analysis was conducted using SAS (version 9.4; SAS
Institute, Cary, NC).
RESULTS
Baseline characteristics for the 93 enrolled patients are
shown in Table 1. The majority of patients were men
with primary tumors that were HPV-positive (93%).
HRQOL data were available for 92 patients at pretreat-
ment, 91 at 3 months, 80 at 12 months, and 70 at 24
months. Videofluoroscopy and salivary flow data were
available, respectively, for 92 and 87 patients at pretreat-
ment, 87 and 79 at 3 months, 81 and 73 at 12 months,
and 65 and 61 at 24 months.
Salivary flow rates and patient-reported xerostomia
Mean SSF rates were 0.87 mL/min (6SD 0.72) prether-
apy, declined to 0.19 mL/min (60.35) at 3 months, and
thereafter improved to 0.29 (60.38), 0.32 (60.33), 0.39
(60.42), and 0.37 (60.38) mL/min at 6, 12, 18, and 24
months posttherapy, respectively. Mean XQ scores pre-
therapy were 6.5 (6SD 13), worsened to 51 (623) and
46 (624) at 3 and 6 months, and thereafter improved to
37 (624), 34 (623), and 31 (622) at 12, 18, and 24
months, respectively.
Assessment of the correlations between SSF rates and
the XQ scores revealed no significant correlation prether-
apy, but statistically significant correlations (p< .05) at
each timepoint posttherapy. Spearman’s correlation coef-
ficients were only modest, however: 20.37, 20.35,
20.55, 20.38, and 20.35 at 3, 6, 12, 18, and 24 months,
respectively (Table 2); the negative coefficients denote
increased (worsened) XQ scores as salivary output
reduced.
Observer-rated dysphagia
ORD grade 2 was infrequent. Grades 2 and 3 dyspha-
gia were observed in 7% and 4% of patients at 6 months,
2.7% and 2% at 12 months, and 1% and 1% at both 18
and 24 months, respectively. Because of the very low fre-
quency of grades 2 ORD at 12 months and beyond,
ORD was not analyzed further.
Functional swallowing assessment by videofluoroscopy
and patient-reported dysphagia
Functional swallowing impairment by Swallowing Per-
formance Status Scale score and PRD by HNQOL-Sw
and UWQOL-Sw score at each timepoint are shown in
Figure 1. Pretherapy Swallowing Performance Status
Scale scores were mostly within functional limits,
whereas at 3 months most scores showed mild-to-
moderate impairment, with 14% showing severe impair-
ment. By 12 and 24 months the rate of patients “within
functional limits” increased to 25% and 32%, respec-
tively, and “severe impairment” was rare. A similar pat-
tern over time was observed in the HNQOL-Sw and
UWQOL-Sw scores (see Figure 1).
Patient-reported dysphagia in patients without
functional swallowing impairment
We next sought to evaluate whether patients without
functional swallowing impairment on videofluoroscopy
may nonetheless perceive the feeling of dysphagia (Table
3). Of 39 patients with either no or mild impairment on
videofluoroscopy (Swallowing Performance Status Scale
score 3) at 3 months, 21% reported at least moderate
swallowing-related bother on the HNQOL-Sw assessment.
On the UWQOL-Sw assessment, 59% of patients with
Swallowing Performance Status Scale score 3 reported
inability to swallow certain solid foods, and 13% reported
swallowing ability limited to only soft foods. At 12 and
24 months, moderate or greater severity swallowing-
TABLE 1. Patient characteristics.
Characteristics Statistics
Male, no. (%) 83 (89)
Age, y, median (range) 56 (40–78)
Primary tumor site, no. (%)
Tonsil 45 (48)
Base of tongue 48 (52)














Smoking history, no. (%)
Never smoker 35 (38)
Former smoker 34 (37)
Current smoker 24 (26)
Pack-years, median (range) 7 (0–140)
Abbreviations: HPV, human papillomavirus; N/A, not available.
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related bother was reported on HNQOL-Sw by 12% and
5% of patients with Swallowing Performance Status Scale
3, respectively. By UWQOL-Sw, 30% of patients with
no/mild videofluoroscopy abnormalities at 12 months
reported inability to swallow certain solid foods and 3%
reported being able to swallow only soft foods; the respec-
tive rates at 24 months were similar at 28% and 3%.
Relationship between patient-reported and functional
assessments of xerostomia and dysphagia
Given that a substantial proportion of patients reported
swallowing problems despite mild or no swallowing
abnormalities on videofluoroscopy, we explored whether
the perception of dysphagia may be related to, and poten-
tially attributable to, PRX. At pretreatment, XQ and
HNQOL-Sw scores were moderately correlated (q 5 0.43;
p< .001), reflecting the high proportion of patients (84%)
who reported either no or slight/mild symptoms (normal-
ized score 25 of 100) on both the XQ and HNQOL-Sw
assessments, consistent with an absence of dysphagia or
xerostomia in most patients pretherapy. Posttreatment, the
strength of the correlation between XQ and HNQOL-Sw
scores increased (q 5 0.57, 0.52, and 0.54 at 3, 12, and
24 months, respectively; all p< .001; Table 2). Similar
magnitude correlations were observed between XQ scores
and UWQOL-Sw scores (q 5 0.33, 0.47, 0.61, and 0.47 at
pretherapy and 3, 12, and 24 months posttreatment,
respectively; all p< .01; Table 2).
In comparison, the correlations between SSF rates and
both HNQOL-Sw scores (q 5 0.014 and p 5 .90 at pre-
therapy; q 5 20.28 and p 5 .01 at 3 months; q 5 20.30
and p 5 .01 at 12 months; and q 5 20.23 and p 5 .08 at
24 months) and UWQOL-Sw scores (q 5 20.12 and
p 5 .27 at pretherapy; q 5 20.19 and p 5 .10 at 3 months;
q 5 20.27 and p 5 .03 at 12 months; and q 5 20.05 and
p 5 .69 at 24 months) showed weaker or nonsignificant
associations than those between the XQ and PRD scores
(Table 2). A comparison of functional assessments of
xerostomia and dysphagia, as measured by SSF rates and
Swallowing Performance Status Scale scores, also showed
weaker or nonsignificant correlations than the correlations
between patient-reported assessments (pretreatment:
q 5 0.03 and p 5 .81; 3 months: q 5 20.31 and p< .01;
12 months: q 5 20.07 and p 5 .58; and 24 months;
q 5 20.37 and p< .01; Table 2). The negative slopes of
these correlations suggested a trend of increasing (wor-
sening) HNQOL-Sw, UWQOL-Sw, and Swallowing Per-
formance Status Scale scores as SSF rates decreased.
Relationship between patient-reported xerostomia and
patient-reported dysphagia in patients without and with
swallowing impairment of videofluoroscopy
Among patients with no/mild evidence of swallowing
impairment on videofluoroscopy (Swallowing Perform-
ance Status Scale score 3) (Table 3), the posttreatment
XQ summary scores remained moderately-to-strongly cor-
related with the HNQOL-Sw scores at all timepoints
(q 5 0.50, 0.60, and 0.41 at 3, 12, and 24 months; p< .01
for all) and with UWQOL-Sw scores at 3 and 12 months
(q 5 0.55 and p< .001 and q 5 0.51 and p 5 .002, respec-
tively; trend at 24 months: q 5 0.27 and p 5 .10). Among
patients with moderate or greater swallowing impairment
on videofluoroscopy (Swallowing Performance Status
Scale score 4), similar significant correlations were
observed between XQ summary scores and both
FIGURE 1. Swallowing impairment pretreatment and after chemoradiation as rated by (A) videofluoroscopy assessment, (B) patient self-
assessment using the Head and Neck Quality of Life (HNQOL) Instrument Swallowing question, and (C) University of Washington Quality of Life
(UWQOL) Instrument Swallowing Question.
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HNQOL-Sw scores (q 5 0.58, 0.32, and 0.48 at 3, 12,
and 24 months; p< .001, p 5 .04, and p 5 .02, respec-
tively) and UWQOL-Sw scores (q 5 0.32, 0.53, and 0.47
at 3, 12, and 24 months; p 5 .03, p< .001, and p 5 .03,
respectively).
Univariate and multivariate regression analyses
Regression analysis was performed to further assess the
relative impact of XQ scores, salivary flow rates, and
Swallowing Performance Status Scale scores on posttreat-
ment HNQOL-Sw and UWQOL-Sw scores. At all post-
treatment timepoints, both XQ scores and Swallowing
Performance Status Scale scores were significantly posi-
tively associated on univariate analysis with PRD by both
HNQOL-Sw and UWQOL-Sw (Table 4). SSF rates were
less associated with HNQOL-Sw and UWQOL-SW scores
than were XQ scores, showing significant associations
with only HNQOL-Sw at 3 months and 12 months, with
trends toward significance at these timepoints for the
UWQOL-Sw endpoint and no association at 24 months
with either HNQOL-Sw or UWQOL-Sw. On multivari-
able analysis (Table 5), the XQ scores remained inde-
pendently associated with both HNQOL-Sw and
UWQOL-Sw scores after adjustment for Swallowing Per-
formance Status Scale scores at nearly all timepoints.
Moreover, the XQ score was a stronger predictor of
HNQOL-Sw and UWQOL-Sw scores than the
TABLE 4. Univariable analysis of association of swallowing impairment










3 mo SPSS score 1.91 <.001 0.652
XQ summary score 4.03 <.001 0.758
SSF 0.54 .035 0.630
12 mo SPSS score 1.75 .021 0.608
XQ summary score 3.77 <.001 0.750
SSF 0.51 .03 0.649
24 mo SPSS score 3.39 <.001 0.754
XQ summary score 3.12 <.001 0.771
SSF 0.80 .37 0.608
UWQOL-Sw
3 mo SPSS score 1.79 .005 0.643
XQ summary score 2.82 <.001 0.729
SSF 0.58 .055 0.587
12 mo SPSS score 3.65 <.001 0.742
XQ summary score 5.80 <.001 0.835
SSF 0.60 .081 0.642
24 mo SPSS score 4.53 <.001 0.795
XQ summary score 3.10 <.001 0.755
SSF 1.01 .974 0.536
Abbreviations: OR, odds ratio; AUC, area under the curve; HNQOL-Sw, Head and Neck Quality
of Life Instrument Swallowing Question; SPSS, Swallowing Performance Status Scale; XQ,
Xerostomia Questionnaire; SSF, stimulated salivary flow; UWQOL-SW, University of Washing-
ton Quality of Life Instrument Swallowing Question.




No. of patients (%) with




bother due to swallowing
problems (HNQOL-Sw)
% reporting inability
to swallow certain foods
(UWQOL-Sw)
% reporting swallowing
limited to only soft foods
(UWQOL-Sw)
3 mo 39 (44) 21 59 13
12 mo 33 (41) 12 30 3
24 mo 39 (60) 5 28 3
Abbreviations: chemo-IMRT, chemotherapy–intensity-modulated radiotherapy; SPSS, Swallowing Performance Status Scale; HNQOL-Sw, Head and Neck Quality of Life Instrument Swallowing
Question; UWQOL-Sw, University of Washington Quality of Life Instrument Swallowing Question.
TABLE 5. Multivariable analysis of impact of swallowing dysfunction by












Model 1 SPSS score 1.98 .001 0.795
XQ summary score 3.99 <.001
Model 2 SPSS score 2.31 <.001 0.708
SSF 0.61 .077
12 mo
Model 1 SPSS score 1.20 .50 0.754
XQ summary score 3.48 <.001
Model 2 SPSS score 1.64 .058 0.702
SSF 0.48 .031
24 mo
Model 1 SPSS score 2.83 .003 0.804
XQ summary score 2.05 .030




Model 1 SPSS score 1.58 .036 0.740
XQ summary score 2.47 <.001
Model 2 SPSS score 2.16 .001 0.704
SSF 0.62 .091
12 mo
Model 1 SPSS score 2.56 .005 0.860
XQ summary score 4.68 <.001
Model 2 SPSS score 3.15 <.001 0.758
SSF 0.59 .12
24 mo
Model 1 SPSS score 4.20 <.001 0.821
XQ summary score 1.74 .12
Model 2 SPSS score 7.67 <.001 0.842
SSF 1.57 .12
Abbreviations: OR, odds ratio; AUC, area under the curve; HNQOL-Sw, Head and Neck Quality
of Life Instrument Swallowing Question; SPSS, Swallowing Performance Status Scale; XQ,
Xerostomia Questionnaire; SSF, stimulated salivary flow; UWQOL-SW, University of Washing-
ton Quality of Life Instrument Swallowing Question.
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videofluoroscopy Swallowing Performance Status Scale
scores at most timepoints. By contrast, the association
between the SSF rates and PRD, after adjustment for vid-
eofluoroscopy Swallowing Performance Status Scale score
on multivariable analysis, was nonsignificant for nearly
all timepoints (Table 5).
DISCUSSION
This study demonstrates that in patients receiving
chemo-IMRT whose planning objectives included the
sparing of both salivary and swallowing-related structures,
PRX was significantly correlated with PRD. The assess-
ment in the current study of both patient-reported out-
comes for dysphagia and xerostomia, as well as the
functional assessments of the related physiological dys-
functions (Swallowing Performance Status Scale scores
and major salivary gland flow rates), highlights the dis-
tinctions in relationships between patient-reported and
functional outcome measures, and indirectly suggests
potential mechanisms through which xerostomia may
affect patient perceptions of dysphagia.
A consistent finding throughout the longitudinal 2-year
assessment period was the highly significant relationships
of both Swallowing Performance Status Scale scores and
XQ scores with PRD. On the other hand, SSF rates,
measured from the major salivary glands, had lower cor-
relations with PRD in the univariate analyses, and were
not significant or of only borderline significance in multi-
variate analysis. Thus, although the functional assessment
of swallowing impairment via videofluoroscopy was
highly predictive of PRD, patients’ subjective perception
of xerostomia was an additional highly significant factor.
One of the reasons for the discrepancy between the
association of XQ scores and SSF rates on PRD is the
weak correlation between xerostomia symptoms and the
measured SSF. The only modest correlation coefficients
of xerostomia symptoms versus salivary output found in
our study posttherapy, despite being statistically signifi-
cant, suggest that SSF explains only part of the variability
in PRX. Although the majority of stimulated saliva during
eating is secreted by the parotid glands, these secretions
are predominantly serous, consisting almost entirely of
water. In contrast, the secretions from the submandibular
glands and especially the minor salivary glands dispersed
within the oral cavity, although relatively of small vol-
umes, are rich in salivary mucins, which adhere to muco-
sal and food particle surfaces to provide lubrication for
food passage and mucosal protection. Mucins bind water
molecules effectively, and their presence on the mucosal
surfaces helps maintain these tissues in a hydrated state
and, importantly, provide a sense of hydration to the
patient.21 Reduced salivary mucins after CRT may greatly
impact the sensation of dry mouth.30 The importance of
the mucin-containing secretions is highlighted in the rela-
tively weak correlations between SSF rates, dominated by
parotid gland secretions, and PRX in our study. They also
explain the failure of randomized studies of parotid-
sparing IMRT to demonstrate a clinically meaningful
advantage in PRX, despite improvements in salivary flow
rates and observer-rated xerostomia in the IMRT arm
compared with the 2D RT arms.19,28 For example,
Nutting et al19 reported that through 12 months after
treatment, the patient-reported benefit of IMRT versus 2D
RT was <10 points on a 0 to 100 scale, regarded not
clinically relevant, despite a large advantage in salivary
output.19 Thus, the SSF measurements, which are pre-
dominantly a measure of the parotid gland secretions,
underestimate the contribution of the mucin-producing
glands. This is reflected in studies demonstrating that, in
addition to mean parotid gland dose, doses delivered to
the submandibular and minor salivary glands affect
PRX.29 The results of the current study emphasize that
their sparing should be an important goal of IMRT opti-
mization, as further improvement in xerostomia is likely
to reduce PRD.
Few previous studies have been published assessing the
association between PRX and dysphagia in patients with
head and neck cancer treated with RT. Logemann et al16
measured whole mouth saliva in patients with head and
neck cancer from pre-RT to 3 months after RT, and com-
pared salivary output to both PRD and videofluoroscopy
results. No significant correlations were found in either
this study or in a follow-up study through 12 months,17
likely because of the very low salivary output in all
patients resulting from 2D-radiation techniques, that pre-
cluded meaningful analysis. These authors concluded that
reduced saliva did not affect the mechanics of swallowing
but seemed to change patients’ perception of their swal-
lowing ability. Our study, in which the SSF rates and XQ
scores recovered after IMRT, showed significant correla-
tions between XQ scores and SSF rates and dysphagia
symptoms even in patients without videofluoroscopy
abnormalities. Further support for a causative, rather than
merely correlative, relationship between xerostomia and
dysphagia is implied by findings in patients with
Sj€ogren’s syndrome, who reported worse dysphagia and
had prolonged food transit time on videofluoroscopy com-
pared with healthy controls.31
The majority of the current literature comparing xero-
stomia and dysphagia after RT in patients with head and
neck cancer had relied upon observer-rated assessments,
yielding conflicting results. Some have reported a signifi-
cant correlation between these toxicities,32 whereas others
have reported no apparent correlation,33 rather showing
that significant xerostomia persisted long after therapy
compared to prompt improvement in dysphagia. Several
retrospective studies comparing parotid-sparing IMRT to
3D-RT noted that, in parallel to improved xerostomia,
swallowing was better in the IMRT-treated patients even
though no specific effort was made to spare the
swallowing-related structures.34–36 On the other hand, a
randomized study of parotid-sparing IMRT versus 3D-RT
found no difference in dysphagia between the arms.19 The
heterogeneous nature of these studies, which included
many patients treated without concurrent chemotherapy,
and therefore were at a lesser risk of dysphagia, compli-
cates accurate evaluation of their results.
The observer-rated Radiation Therapy Oncology Group/
European Organisation for Research and Treatment of
Cancer scale for dysphagia, which is very similar to the
Common Terminology Criteria for Adverse Events evalu-
ation grading system, disclosed very few patients with
grades 2 at 12 months and beyond, similar to our prior
report in patients treated with swallowing–structure-
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sparing IMRT.11 The low frequency of ORD events pre-
cluded statistical evaluation of correlates with this end-
point. In contrast, patient-reported scores showed a wide
distribution. We have previously reported the discrepan-
cies between ORD and PRD in assessing the relative
severity of dysphagia, showing that videofluoroscopy
results were more consistent with patient-reported than
observer-rated scoring.37 We therefore prefer using
patient-reported outcomes as the most reliable way to
assess dysphagia and other sequelae of treatment.
In conclusion, in this longitudinal study of chemo-
IMRT for patients with oropharyngeal cancer, PRX was a
significant contributor to patients’ perception of dyspha-
gia, irrespective of evidence of functional swallowing
impairment and despite the use of organ-sparing IMRT
techniques. Efforts to decrease treatment-related xerosto-
mia by increased salivary gland sparing, including the
submandibular and minor oral cavity salivary glands in
addition to sparing the parotid glands,25 are likely to
translate into improvements in patients’ perception of
dysphagia after CRT for head and neck cancer.
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